Global Liraglutide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Liraglutide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
Liraglutide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Liraglutide market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Drug Store are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Liraglutide industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Liraglutide key manufacturers include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, etc. HEC Pharm, Bachem, Bharat Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Liraglutide can be divided into Pills and Liquid, etc. Pills is the mainstream product in the market, accounting for % sales share globally in 2022.
Liraglutide is widely used in various fields, such as Hospital and Drug Store, etc. Hospital provides greatest supports to the Liraglutide industry development. In 2022, global % sales of Liraglutide went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liraglutide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
Segment by Type
Pills
Liquid
Hospital
Drug Store
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Liraglutide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Liraglutide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Liraglutide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Liraglutide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Liraglutide introduction, etc. Liraglutide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Liraglutide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Liraglutide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Liraglutide market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Drug Store are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Liraglutide industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Liraglutide key manufacturers include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, etc. HEC Pharm, Bachem, Bharat Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Liraglutide can be divided into Pills and Liquid, etc. Pills is the mainstream product in the market, accounting for % sales share globally in 2022.
Liraglutide is widely used in various fields, such as Hospital and Drug Store, etc. Hospital provides greatest supports to the Liraglutide industry development. In 2022, global % sales of Liraglutide went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liraglutide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
Segment by Type
Pills
Liquid
Segment by Application
Hospital
Drug Store
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Liraglutide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Liraglutide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Liraglutide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Liraglutide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Liraglutide introduction, etc. Liraglutide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Liraglutide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.